Compared with traditional surgery, surgical robot has obvious advantages. "Da Vinci surgical robot" is an endoscopic surgical instrument control system, which is widely used in urology, general surgery, gynecology, cardiothoracic surgery and other clinical departments. Compared with traditional minimally invasive surgery, surgical robot is more precise and accurate, and has certain advantages in terms of operation and hospitalization time, reducing bleeding, complication rate and postoperative recovery, which can obviously improve the quality of life of patients after operation.
For example, surgical robots have obvious advantages in prostate cancer resection. Under the general excision method, some patients will lose their sexual function, because the sexual nerve is extremely slender and cannot be observed with the help of ordinary medical equipment, and the surgical robot can allow a higher proportion of patients to retain the right of "sexual happiness".
Under laparoscope, doctors can only see the black-and-white plane with twice magnification, while the surgical robot can realize 3D color and magnification of 10- 15 times. Laparoscopic surgery is controlled by human hands, and hand trembling will be amplified at the end, which will affect the accuracy of the operation. The surgical robot is controlled by a doctor operating a computer, and there is no jitter problem.
In addition, the amount of bleeding in robotic surgery is greatly reduced, which also helps to alleviate the increasingly serious "blood shortage". Taking patients with gastric cancer as an example, conventional surgery generally requires about 400 ml of blood transfusion, while robotic surgery generally does not require blood transfusion or only needs 50 ml.
Some domestic companies have avoided "
leonardo di ser piero da vinci
Robot "and other advantages, to the orthopedics, neurosurgery, interventional surgery and other fields.
Get good results. Tianzhihang's chiropractic robot and Baihui Weikang's "Ruimi" neurosurgery robot have successfully passed the examination of the third kind of medical devices, and they have gone further and further in broadening the functional boundaries of surgical robots.
Treatment application of domestic surgical robot enterprises
In 20 18 years, the clinical trials of gastric cancer surgery in five hospitals, such as Japan's Tongshe University Hospital, Saga University Hospital, etc.18 years showed that robotic endoscopic surgery had fewer complications than traditional abdominal endoscopic surgery. After tasting the sweetness of surgical robots, Japan immediately announced that it would
12 kinds of endoscopic surgery with robot subsidy are included in the insurance scope, including gastric cancer, colorectal cancer, lung cancer and other operations.
02
The dilemma of domestic surgical robots needs to be solved urgently.
Da Vinci surgical robot is the most successful and widely used surgical robot in the world, monopolizing the surgical robot market by more than 20%.
In, it was regarded as the "myth" of the medical device industry. According to statistics, as of 20 19, the global installed capacity of Leonardo da Vinci robots has reached 5,582, and the cumulative number of operations has reached 7.2 million.
The total number of operations using Da Vinci robots surged 18%, reaching nearly 1.23 million operations worldwide.
On average, every 26 seconds, a doctor in the world uses the Ada Finch robot for surgery.
Many coveted adventurers poured into this market with a market value of hundreds of billions. Traditional leading enterprises, such as Medtronic, Johnson & Johnson, Stryker, Jiemai and Xerox. , has completed the layout in the field of surgical robots through acquisitions, mergers, acquisitions, etc., and has continuously extended its boundaries and raced around, with the intention of competing with Leonardo da Vinci in many fields.
Surgical robot is a field with high technical threshold, long development, registration and marketing cycle, and extremely expensive money. No matter how well the product is made, it is useless to miss the market opportunity window. No matter how low the price is, it may not sell well. Although China's surgical robot market has completed early market education, due to technological innovation ability, innovation chain, incomplete industrial chain and other factors, the technical competitiveness of high-end diagnostic equipment for surgical robots in China is weak, and domestic enterprises represented by Tianzhihang, Baihui Weikang and Miaoshou Robot have joined the track one after another.
Under the attack of several international giants, it is really difficult for domestic surgical robot enterprises to achieve profitability. Like Tianzhihang, it has an absolute advantage in the domestic orthopedic market. By the first half of 2020, Tianzhihang has been realized.
104 patents; By the end of 20 19, it has been put into clinical use in 74 medical institutions, including 52 top-class hospitals, accounting for more than 70%.
But Tian Zhihang
The annual results in 2020 show that there is still no way to get rid of the situation of losses in successive years. With the introduction of orthopedic surgery robot treatment into the charging catalogue of provinces and cities, especially the implementation of Shanghai medical insurance policy, Tianzhihang's marketing model and revenue are expected to usher in a major turn for the better.
According to population statistics, the elderly population in China will be close to 500 million. By then, more medical resources will be needed. But the reality is that the population in China is decreasing, the doctor-patient relationship is poor, the salaries of doctors and nurses are low, and the enrollment of university medical schools has been declining in recent years, which is a signal. Surgical robots can alleviate this problem. Doctors can operate the machine far from the operating table. The surgical robot consists of a console and an operating arm. With the cooperation of computer system, operation monitor, robot control monitor, input and output equipment, etc. , you can complete more detailed medical operations. If surgical robots are included in medical insurance and widely popularized, the amount of surgery will be greatly increased and people's medical needs will be greatly improved.
20 18 April, Japan announced that 12 kinds of endoscopic surgery subsidized by robots were included in the insurance coverage, including gastric cancer, colorectal cancer, lung cancer and other operations. The price of buying a "Da Vinci" is about 200 million yen to 300 million yen, but the hospital "has the money" to buy robot surgery equipment is really not enough. In an interview with Yomiuri Shimbun, Watanabe, president of the Japanese Society of Robotic Surgery, said: "Robotic surgery is by no means something that anyone can master. It is very important to keep repeating training to achieve safe operation. " Japanese surgical robots have long been included in the scope of medical insurance, and China's surgical robots are not far away.